

Clement Chung

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5836440/publications.pdf>

Version: 2024-02-01

28
papers

393
citations

840776

11
h-index

794594

19
g-index

28
all docs

28
docs citations

28
times ranked

629
citing authors

#	ARTICLE	IF	CITATIONS
1	Predictive and prognostic biomarkers with therapeutic targets in breast, colorectal, and non-small cell lung cancers: A systemic review of current development, evidence, and recommendation. <i>Journal of Oncology Pharmacy Practice</i> , 2014, 20, 11-28.	0.9	54
2	Implementation of an integrated computerized prescriber order-entry system for chemotherapy in a multisite safety-net health system. <i>American Journal of Health-System Pharmacy</i> , 2018, 75, 398-406.	1.0	43
3	Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy. <i>Pharmacotherapy</i> , 2017, 37, 129-143.	2.6	34
4	Ziv-aflibercept: A novel angiogenesis inhibitor for the treatment of metastatic colorectal cancer. <i>American Journal of Health-System Pharmacy</i> , 2013, 70, 1887-1896.	1.0	31
5	Restoring the switch for cancer cell death: Targeting the apoptosis signaling pathway. <i>American Journal of Health-System Pharmacy</i> , 2018, 75, 945-952.	1.0	31
6	Development and implementation of an interdisciplinary oncology program in a community hospital. <i>American Journal of Health-System Pharmacy</i> , 2011, 68, 1740-1747.	1.0	26
7	Tyrosine kinase inhibitors for epidermal growth factor receptor gene mutation-“positive non-small cell lung cancers: an update for recent advances in therapeutics. <i>Journal of Oncology Pharmacy Practice</i> , 2016, 22, 461-476.	0.9	26
8	Current targeted therapies in lymphomas. <i>American Journal of Health-System Pharmacy</i> , 2019, 76, 1825-1834.	1.0	19
9	Pertuzumab for the treatment of human epidermal growth factor receptor type 2-positive metastatic breast cancer. <i>American Journal of Health-System Pharmacy</i> , 2013, 70, 1579-1587.	1.0	14
10	Trametinib: A novel signal transduction inhibitor for the treatment of metastatic cutaneous melanoma. <i>American Journal of Health-System Pharmacy</i> , 2015, 72, 101-110.	1.0	14
11	Ibrutinib, Obinutuzumab, Idelalisib, and Beyond: Review of Novel and Evolving Therapies for Chronic Lymphocytic Leukemia. <i>Pharmacotherapy</i> , 2014, 34, 1298-1316.	2.6	12
12	Driving Toward Precision Medicine for Acute Leukemias: Are We There Yet?. <i>Pharmacotherapy</i> , 2017, 37, 1052-1072.	2.6	12
13	Management of neuroendocrine tumors. <i>American Journal of Health-System Pharmacy</i> , 2016, 73, 1729-1744.	1.0	11
14	From oxygen sensing to angiogenesis: Targeting the hypoxia signaling pathway in metastatic kidney cancer. <i>American Journal of Health-System Pharmacy</i> , 2020, 77, 2064-2073.	1.0	11
15	Omacetaxine for treatment-resistant or treatment-intolerant adult chronic myeloid leukemia. <i>American Journal of Health-System Pharmacy</i> , 2014, 71, 279-288.	1.0	9
16	An update on current and emerging therapies for epithelial ovarian cancer: Focus on poly(adenosine) Tj ETQq0 0 0 rgBT /Overlock 10 Tf Practice, 2017, 23, 454-469.	0.9	9
17	Predictive and prognostic biomarkers with therapeutic targets in colorectal cancer: A 2021 update on current development, evidence, and recommendation. <i>Journal of Oncology Pharmacy Practice</i> , 2022, 28, 850-869.	0.9	9
18	To do or not to do: A concise update of current clinical controversies in immune checkpoint blockade. <i>Journal of Oncology Pharmacy Practice</i> , 2019, 25, 663-673.	0.9	8

#	ARTICLE	IF	CITATIONS
19	New Therapeutic Targets and Treatment Options for Thrombotic Microangiopathy: Caplacizumab and Ravulizumab. <i>Annals of Pharmacotherapy</i> , 2021, 55, 330-343.	1.9	5
20	Targeting the androgen receptor signaling pathway in advanced prostate cancer. <i>American Journal of Health-System Pharmacy</i> , 2022, 79, 1224-1235.	1.0	5
21	Driving toward precision medicine for B cell lymphomas: Targeting the molecular pathogenesis at the gene level. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 943-966.	0.9	4
22	Older adults may not consider life expectancy an important factor in cancer screening. <i>Ca-A Cancer Journal for Clinicians</i> , 2018, 68, 3-4.	329.8	2
23	Risk of ovarian function recovery should be considered when switching from treatment with adjuvant tamoxifen to aromatase inhibitor therapy in women with chemotherapy-induced amenorrhea. <i>Ca-A Cancer Journal for Clinicians</i> , 2018, 68, 5-6.	329.8	2
24	Targeting the Myeloid Lineages and the Immune Microenvironment in Myelodysplastic Syndromes: Novel and Evolving Therapeutic Strategies. <i>Annals of Pharmacotherapy</i> , 2021, , 106002802110361.	1.9	1
25	Optimizing Multidisciplinary Treatment-Related Adverse Effects Detection and Reduction in Patients Undergoing Active Cancer Treatments in Ambulatory Infusion Centers. <i>JCO Oncology Practice</i> , 2022, 18, e1553-e1561.	2.9	1
26	Importance of ethnicity and smoking status in <i>EGFR</i> gene testing in lung cancers. <i>American Journal of Health-System Pharmacy</i> , 2015, 72, 686-686.	1.0	0
27	Instilling value, quality, and safety through hematology and oncology stewardship. <i>American Journal of Health-System Pharmacy</i> , 2019, 76, 617-621.	1.0	0
28	Misconception on the duration of ado-trastuzumab emtansine treatment for HER2-positive early breast cancer. <i>American Journal of Health-System Pharmacy</i> , 2022, , .	1.0	0